Context: Dipeptidyl peptidase 4 (DPP-4) metabolizes glucagon-like peptide-1 (GLP-1), and increased DPP4 levels are associated with obesity and visceral adiposity in adults.
secretion (3) . The two most studied incretin hormones are glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1). We recently showed that plasma levels of intact GLP-1 during an oral glucose tolerance test (OGTT) was lowered in adolescents with T2DM who were obese (4) . The intact form of GLP-1 has an in vivo half-life of only a couple of minutes because of rapid inactivation by the serine protease dipeptidyl peptidase 4 (DPP-4), also known as CD26 (3) . Several tissues express DPP-4, and it is present in two forms in humans: a transmembrane form and a soluble form, the latter circulating in the bloodstream (5) . The soluble form is released to the circulation through shedding from plasma membranes. Both the membrane-bound and soluble forms of DPP-4 have catalytic activity (6) . Leukocytes, the liver, and adipose tissue have been suggested as sources for circulating DPP-4, although the relative contributions from different tissues are not known (7) (8) (9) (10) . Sell et al. (8) showed that in adults, mRNA expression of DPP-4 in biopsies from visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) was correlated with body mass index (BMI) and that circulating DPP-4 concentrations were correlated with VAT area. In a study of healthy adults, plasma DPP-4 activity was observed to be an independent predictor of insulin resistance, impaired glucose tolerance (IGT), and T2DM, suggesting that DPP-4 plays a role in the etiology of T2DM (11) . The importance of DPP-4 is also underlined by the beneficial effects that pharmacological inhibitors of DPP-4, known as gliptins, have on glucose homeostasis in T2DM (12) .
Despite knowledge of the importance of DPP-4, little is known about circulating DDP-4 in children and adolescents with obesity and IGT. This study aimed at investigating circulating DPP-4 in children and adolescents and its association with (1) circulating intact GLP-1 levels; (2) BMI and glucose tolerance; and (3) visceral, subcutaneous, and liver fat compartments.
Materials and Methods

Study population
The study population consisted of children and adolescents with overweight or obesity (n = 59) and lean children and adolescents (n = 21). Subjects were recruited from the childhood obesity clinic at Uppsala University Children's Hospital and, in the case of the lean children and adolescents, from advertisements and from a local school. All study subjects were part of the Uppsala Longitudinal Study of Childhood Obesity cohort (13) . Subjects with obesity were treated through a lifestyle intervention program, including advice regarding diet and physical exercise (13) . Subjects visited the clinic between July 2012 and April 2015. Inclusion criteria were age ,19 years, and for lean controls, BMI SD score (BMI SDS) #1, and for the overweight/obesity group, BMI SDS .1. The exclusion criterion was ongoing pharmaceutical antihyperglycemic treatment. The hyperglycemia of patients included in the current study was thus screen detected and therefore not treated at the time of inclusion in the study. Body weight was measured by a digital scale and height by a wall-mounted stadiometer. BMI was calculated, and the BMI SDS was determined according to the World Health Organization's 2006 to 2007 reference population (14) . The BMI SDS serves as an age-and sex-adjusted BMI for comparisons across childhood and adolescence. Waist and hip circumferences were measured to the nearest centimeter by a flexible tape, and the waist/hip ratio was calculated. Written informed consent was obtained from study subjects and their legal guardians. The local ethics committee approved the study (Reg no. 2012/318).
Blood sampling and OGTT
A standard OGTT was performed as previously described (13) . Briefly, subjects drank glucose (APL, Stockholm, Sweden) dissolved in water. The glucose dose was 1.75 g/kg of body weight, with a maximum of 75 g total. Blood was sampled through a patent venous catheter, which was applied after local anesthesia by a skin patch (EMLA; AstraZeneca, Cambridge, UK). Blood samples for biobank storage were immediately placed on ice and centrifuged at 4°C and 2500g for 10 minutes, after which plasma was aliquoted and stored at 280°C until analyses. Subjects were classified as having normal glucose tolerance (NGT) or IGT according to the World Health Organization (i.e., subjects with a 2-hour glucose level ,7.8 mmol/L were classified as NGT, and those with a level $7.8 mmol/L were classified as IGT).
Biochemical analyses
Plasma concentrations of DPP-4 were quantified by sandwich ELISA (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions. Total GLP-1 was measured by a sandwich chemiluminescent immunoassay (Mercodia, Uppsala, Sweden) that detects the amidated forms of GLP-1, including the predominating intact isoform GLP-1 (7-36) amide and the predominating metabolized isoform GLP-1 (9-36) amide. Intact GLP-1 was measured by electro-chemiluminescent immunoassay (Meso Scale Discoveries, Rockville, MD), detecting GLP-1 (7-36) amide and with 31% cross-reactivity to GLP-1 (7-37). Plasma DPP-4 activity was determined by an enzyme activity kit with a chromogenic substrate for DPP-4 (Enzo Life Sciences, Farmingdale, NY). Plasma insulin concentrations were quantified by sandwich ELISA (Mercodia). Insulin concentration and DPP-4 concentration and activity were determined from biobank plasma samples collected through EDTA-containing vacutainer tubes (Becton Dickinson, Franklin Lakes, NJ). Total GLP-1 and intact GLP-1 levels were quantified from biobank plasma samples collected in P800 vacutainer tubes (Becton Dickinson, Franklin Lakes, NJ) containing DPP-4 inhibitor, protease inhibitors, and elastase inhibitors. Blood glucose value was analyzed from venous blood by using a glucose oxidation method, and alanine aminotransferase (ALAT) and g-glutamyltransferase (g-GT) were analyzed according to the International Federation of Clinical Chemistry and Laboratory Medicine method (Architect instrument; Abbott Diagnostics) by the Uppsala University Hospital laboratory.
MRI
In a subset of subjects with overweight or obesity (n = 44) and lean controls (n = 18), VAT and SAT volumes and liver fat fraction (LFF) were determined by MRI of the abdomen as previously described (15) . In brief, 1.5-T clinical MRI systems (Philips Medical System, Amsterdam, Netherlands) were used. Water-fat imaging techniques were used throughout. All MRIscans were performed after a light meal and in close proximity to the OGTT, in most cases on the same day. The scans were done over 16.8 cm along the craniocaudal axis and centered on L2-L3. The adipose tissue volumes were determined using a fully automated segmentation method that uses a filtering technique to separate VAT from SAT. Liver fat image reconstruction was done by a multiresolution version of a method that employs a wholeimage optimization approach (16) . A single operator trained by an experienced radiologist performed the measurements by manual segmentation in the axial slices of the water images using the software ImageJ (version 1.42q; rsbweb.nih.gov/ij/). The median fat fraction value in the segmented liver was used as estimated LFF.
Statistical analysis
Differences in DPP-4 and GLP-1 between the obesity and the lean groups and differences in DPP-4 concentrations between males and females were analyzed by nonpaired Student t test or Mann-Whitney U test where appropriate, according to the distribution of data. Normality of data distribution was determined by the Shapiro-Wilk test and the examination of QQplots. Area under the curve (AUC) was calculated by the trapezoid method with zero as baseline. The proportion of intact GLP-1 (in percentage) was calculated as fasting intact GLP-1/total GLP-1 or intact GLP-1 AUC/total GLP-1 AUC multiplied by 100. Associations between plasma concentrations of DPP-4 and anthropometric measurements, fat compartments, and biochemical analytes were analyzed by linear regression with and without adjusting for age and sex as confounders. In the analyses of associations between plasma DPP-4 and biochemical analytes, the lean and obesity groups were studied separately to avoid confounding by obesity. The difference in elevation of regression lines between the lean and obesity groups in the association between plasma DPP-4 and age was analyzed by analysis of covariance. Statistical analysis was done with GraphPad Prism v6.0 (GraphPad Software, La Jolla, CA) and SPSS v22 (IBM Corp, Armonk, NY).
Results
There were no major differences in age, distribution of males/females, or pubertal status between the obesity and lean groups (Table 1 ). In the obesity group, 26 patients had NGT and 34 had IGT. In the lean controls, all but one subject had NGT; the one lean subject with IGT was just above the 2-hour glucose limit, with a value of 7.8 mmol/L. The range of fasting glucose levels was 4.6 to 6.4 mmol/L in the lean group and 5.0 to 6.6 mmol/L in the obesity group. The range of 2-hour glucose was 3.4 to 7.8 mmol/L in the lean group and 5.1 to 11.1 mmol/L in Values are mean 6 SD for normally distributed parameters and median with interquartile range for non-normally distributed parameters. a P , 0.001 vs lean group.
b MRI measurement performed only in a subset of subjects, n = 18 in lean group and n = 43 in obesity group.
c P , 0.01 vs lean group.
d P , 0.05 vs lean group.
the obesity group, and the range of HbA1c was 24 to 39 mmol/mol in the lean group and 26 to 44 mmol/mol in the obesity group. Plasma concentrations of DPP-4 correlated with plasma DPP-4 enzyme activity measured in a subset of the study subjects (P , 0.001; Supplemental Fig. 1 ). Plasma DPP-4 level in the lean group decreased by 48 ng/mL per year (95% CI: 288, 27 ng/mL) and by 41 ng/mL per year (95% CI: 269, 213 ng/mL) in the obesity group [ Fig. 1(a) ]. Although slopes of regression were similar in the lean and obesity groups, the elevation of the regression line in the obesity group was higher than the line in the lean control group (P = 0.02); that is, at the same age, fasting plasma DPP-4 level was higher in subjects who were obese than in lean subjects. With adjustment for the influence of age, males had higher fasting plasma DPP-4 concentrations than females [ Fig. 1(b) ]; this was true for both the lean and obesity groups. The effect of obesity on plasma DPP-4 level was larger in females (789 vs 600 pg/mL in the obesity group vs the lean group) than in males (970 vs 889 pg/mL, respectively) [ Fig, 1(b) ]. Henceforth, associations with DPP-4 were adjusted for age and sex as potential confounders.
The regression coefficients for the associations between plasma DPP-4 and anthropometric measurements are presented in Table 2 . The regression coefficient was 36 ng/mL (95% CI: 2.1, 69.8 ng/mL) for BMI SDS and 856 ng/mL (95% CI: 163, 1549 ng/mL) for waist/hip ratio. The association between plasma DPP-4 and BMI SDS was stronger in females than in males [47 ng/mL (95% CI: 210, 104 ng/mL) vs 28 ng/mL (95% CI: 216, 71 ng/mL)] [ Fig. 1(c) ]. This was also true for the association between plasma DPP-4 and waist/hip ratio [1137 ng/mL (95% CI: 235, 2138 ng/mL) in females vs 465 ng/mL (95% CI: 2600, 1529 ng/mL) in males]. The regression coefficients were 0.05 ng/mL (95% CI: 20.02, 0.12 ng/mL) for VAT [ Fig. 1(d) ], 0.007 ng/mL (95% CI: 20.01, 0.03 ng/mL) for SAT [ Fig. 1(e) ], and 1.9 ng/mL (95% CI: 20.9, 11.5 ng/mL) for LFF. To investigate whether the increase in DPP-4 with obesity was mediated through an increase in SAT or VAT, these were both added together with age and sex to a regression model with DPP-4 as the dependent variable. This increased the correlation coefficient estimate of VAT to 0.11 (95% CI: 20.02, 0.24), whereas it decreased the correlation coefficient estimate of SAT to 20.02 (95% CI: 20.05, 0.02).
Although observed concentrations of intact GLP-1 in the obese children were similar to those in the lean controls, their levels of total GLP-1 at fasting were 1.5-fold higher than those of lean controls (Table 1 ). In the children and adolescents with obesity, the rise in intact and total GLP-1 levels during OGTT (i.e., the AUC) was 83% and 78%, respectively, of that in the lean children ( Table 1 ).
The regression coefficients for the associations between plasma DPP-4 and plasma glucose, GLP-1, and liver enzymes are presented in Table 3 for the obesity group and in Supplemental Table 1 for the lean group. In the obesity group, regression coefficients were 212.3 ng/mL (95% CI: 222.9, 21.8 ng/mL) and 212.1 ng/mL (95% CI: 222.5, 21.7 ng/mL) for proportions of intact GLP-1 at fasting and during OGTT, respectively ( Fig. 2; Table 3 ). In the lean group, regression coefficients were similar, although not statistically significant ( Fig. 2; Supplemental Table 1 ).
Discussion
The main findings of the current study are that high plasma DPP-4 concentrations in children and adolescents were (1) associated with low proportions of intact GLP-1 but not with glucose tolerance, (2) higher in obesity, and (3) associated with visceral rather than subcutaneous or liver fat. Furthermore, the plasma DPP-4 level was higher in males and decreased with age throughout adolescence.
In our study subjects, DPP-4 concentrations were associated with a lower proportion of GLP-1 in its intact form, both at fasting and during OGTT. Although there was no difference in fasting concentrations of intact GLP-1 between subjects with obesity and lean subjects, in the obese subjects, the fasting plasma total GLP-1 level was higher. One possible explanation is that the metabolism of GLP-1 in the circulation is augmented in obese children and adolescents and accompanied by a compensatory higher secretion of GLP-1 to maintain intact GLP-1 concentrations at fasting. A previous study in adults found lowered concentrations of both intact and total GLP-1 together with higher plasma DPP-4 activity in obesity (17) . However, in obesity the concentrations of intact GLP-1 were lowered to a greater extent than those of total GLP-1 (17) , which is in line with the findings of the current study. Despite the associations between DPP-4 plasma concentrations and the proportion of circulating intact GLP-1, plasma DPP-4 concentrations were not associated with higher 2-hour glucose values. Thus, our results indicate that elevated plasma DPP-4 concentrations are unlikely to be a driving factor behind the development of IGT in childhood obesity.
Plasma DPP-4 concentrations were 19% higher in children and adolescents with obesity, which is a finding similar to most (17) (18) (19) (20) , but not all (21, 22) , studies in adults. The only previous study in childhood obesity found that weight loss was associated with lowered DPP-4 levels (23). The association with waist/hip ratio indicates that android obesity rather than gynoid obesity is associated with elevated plasma DPP-4 concentrations. In the MRI results of the abdominal adipose tissue compartments, an increase in VAT rather than SAT was related to the obesity-associated increase in plasma DPP-4 level, although none of the associations were statistically significant. Previous studies in adults have found correlations between plasma DPP-4 level and estimates of VAT area (8, 20) . DPP-4 expression and release are higher from VAT than from SAT extracts (8, 24) . Macrophages derived from the adipose tissue have been shown to release lesser amounts of DPP-4 in comparison with adipocytes, making the adipocyte the most likely major source of DPP-4 from adipose tissue (24) . Thus, a possible explanation for the previously observed associations between DPP-4 and VAT is that a larger VAT releases more DPP-4 into the circulation. However, our estimate of the effect of VAT on plasma DPP-4 level was low (+0.05 ng/mL per cm 3 increase of VAT); considering a theoretical change from the lean average to the obese average in VAT, this would correspond to an 83 ng/mL increase in plasma DPP-4 level. Indeed, the VAT volume in the obesity group was on average 6.4 times larger than the volume in lean subjects, whereas circulating DPP-4 concentrations were on average only 1.2 times higher in the obesity group than in the lean subjects. Thus, if VAT is an important source of circulating DPP-4 in childhood and adolescence, its release per unit of fat mass must be drastically lower in obesity or the elimination much higher.
The association between age and DPP-4 in our study indicates a rapid decline in DPP-4 concentrations throughout adolescence and puberty in both lean and obese adolescents. This is in line with results from a previous study of DPP-4 in the serum of children and adolescents 1 to 17 years old, which found peak DPP-4 concentrations at around 10 years of age (25) . The 17-and 18-year-old adolescents in the current study had average plasma DPP-4 concentrations comparable to those described in adults (8) . Plasma concentrations of DPP-4 also seem to decrease with age throughout adulthood (24) . Taken together, it seems that plasma concentrations of DPP-4 decrease from around 10 years of age and throughout adolescence and adulthood. The decline of plasma DPP-4 concentrations in adolescence coincides with the decline in T-cell production by the thymus (26) . It has been suggested that DPP-4 is shedded from T-cells and that DPP-4 is known to be involved in T-cell activation and proliferation (9, 27) . Indeed, Klemann et al. (28) found that genetic DPP-4 deficiency in mice resulted in altered thymus architecture, a decreased number of proliferating cells in the thymus, reduced density of lymphocytes in the medulla, and a marked reduction in the number of B cells later in life. In addition, DPP-4 has been described as a marker of aggressiveness in T-cell malignancies; indeed, DPP-4 has been studied in relation to the tumor process, where its effect on carcinogenesis varies in different cell types (29) . Another indication of the involvement of DPP-4 in the immune system is that infections are reported side effects of pharmacological DPP-4 inhibition, although the long-term immunological effects of DPP-4 inhibition are not fully known (27) . In the current study, plasma concentrations of DPP-4 were higher in males than in females, both in obesity and in lean subjects. This was also found in a recent study of mostly normal weight and young adults (21) . Plasma DPP-4 concentrations were recently shown to be elevated in women with polycystic ovary syndrome, and DPP-4 mRNA expression was increased by androgens in vitro (30) . Thus, it is possible that the male sex and androgens also influence DPP-4 levels through mechanisms other than increased VAT. Our data are compatible with mechanisms other than increased VAT being more important in mediating the effect of sex on plasma DPP-4. Interestingly, the associations between obesity (BMI SDS) and waist/hip ratio on plasma DPP-4 level was stronger in females than in males. When the females were divided into groups by premenarche and postmenarche, the postmenarche group had significantly lower DPP-4 concentrations (data not shown). However, whether this is an effect of pubertal status or the decline is related to the demonstrated age decline we showed with DPP-4 [ Fig. 1(a) ] is unclear. Interestingly, males tend to reach puberty about 2 years later than females do, and males also seemed to have a later decline of DPP-4 concentrations in our material. A more detailed investigation of the relationship between sex hormones and DPP-4 concentrations is an interesting topic for future study. Because lean male subjects had higher plasma DPP-4 levels than female subjects with obesity, the effect of sex on plasma DPP-4 level is likely stronger than that of obesity in adolescents. Thus, in males with already high plasma DPP-4 levels, obesity does not do as much to plasma DPP-4 concentrations as in females with normally low DPP-4 levels. A suggested summary and interpretation of the observed associations are presented in Fig. 3 .
Limitations to the current study include low precision in several of the estimates of regression coefficients, especially in the subgroup analysis of the lean group because of the limited number of subjects. Also, enzymes other than DPP-4 in the circulation might contribute to plasma DPP-4 activity and affect the levels of intact GLP-1. Thus, by assuming that plasma DPP-4 concentrations reflect DPP-4 activity, we may have underestimated an effect of plasma DPP-4 activity on the proportion of intact GLP-1. Furthermore, the obesity group had a larger proportion of postpubertal adolescents than the lean group, although it was not statistically significantly different. Because the DPP-4 level decreases with age, this difference between the groups could lead us to underestimate a difference in plasma DPP-4 concentrations between obese and lean adolescents.
In conclusion, plasma DPP-4 level is slightly elevated in childhood obesity, and this elevation seems related to visceral fat rather than subcutaneous or liver fat compartments. A high plasma DPP-4 level is associated with lower GLP-1 in its intact form. These associations are compatible with an increased GLP-1 metabolism in childhood obesity, but this does not seem related to IGT. Furthermore, plasma DPP-4 level is higher in males than in females and decreases with age throughout adolescence. Although GLP-1 analogues have shown promising effects on obesity in adolescents (31), treatment with DPP-4 inhibitors has not been evaluated in children (32) . The finding of higher plasma DPP-4 levels in childhood and rapid decline through adolescence in lean subjects in the current study suggests a physiological role of DPP-4 in this age group. In our opinion, although DPP-4 inhibitor treatment has positive effects in adults, our data together with existing experimental data on the role of DPP-4 in immune system development (27) and with the relationship between DPP-4 and tumor biology (29) need to be considered when DPP-4 inhibitors are evaluated as a treatment option in childhood obesity.
